<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 11pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Date of Report (Date of Earliest Event Reported):
January 25, 2012 (January 23, 2012)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Cleveland BioLabs, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact Name of Issuer as Specified in Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 32%; vertical-align: top; font-weight: bold; text-align: center">DELAWARE</TD>
    <TD STYLE="width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 32%; vertical-align: top; font-weight: bold; text-align: center">001-32954</TD>
    <TD STYLE="width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 32%; vertical-align: top; font-weight: bold; text-align: center">20-0077155</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">(State or Other Jurisdiction of Incorporation or Organization)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">(Commission File Number)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">(I.R.S. Employer Identification Number)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 49%; vertical-align: top; font-weight: bold; text-align: center">73 High Street</TD>
    <TD STYLE="width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 49%; vertical-align: top; font-weight: bold; text-align: center">14203</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center">Buffalo, NY</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">(Zip Code)</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">(Address of Principal Executive Offices)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>(716) 849-6810</U></B><U> </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&rsquo;s Telephone Number, Including
Area Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former Name or Former Address, if Changed Since
Last Report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-family: Wingdings">o</TD>
    <TD>Written communications pursuant to Rule 425 under the Securities Act</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-family: Wingdings">o</TD>
    <TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-family: Wingdings">o</TD>
    <TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-family: Wingdings">o</TD>
    <TD>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) and (c)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 24, 2012, Cleveland BioLabs, Inc.
(the &ldquo;Company&rdquo;) announced that Michael Fonstein, Ph.D. has stepped down from his position as Chief Executive Officer
of the Company. He will continue to serve as the President of the Company. The Company also announced that Yakov Kogan, Ph.D.,
M.B.A., the current Chief Operating Officer of the Company, will also be appointed to the position of interim Chief Executive Officer.
The above changes will take effect immediately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The change is being implemented in order to
focus Dr. Fonstein&rsquo;s time and effort on advancing the CBLB502 program towards FDA licensure as a countermeasure for Acute
Radiation Syndrome, guiding promising business development opportunities and supporting recently established joint ventures. Dr.
Kogan, as interim Chief Executive Officer, will become the principal executive officer of the Company in charge of all of the Company&rsquo;s
strategic and operational activities. Both Dr. Fonstein and Dr. Kogan will remain employed as executives of the Company pursuant
to their existing employment agreements and will retain their positions as members of the Company&rsquo;s Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to his appointment as interim Chief Executive
Officer, Dr. Kogan served as the Chief Operating Officer of the Company. His biographical information is contained in the Company&rsquo;s
proxy statement for the Company&rsquo;s 2011 Annual Meeting of Stockholders, and is incorporated herein by reference. Leah Brownlee,
who serves as the Company&rsquo;s General Counsel and Vice President of Corporate Compliance, is the spouse of Dr. Kogan. During
fiscal 2011, as compensation, Ms. Brownlee was paid $200,313 in cash salary and bonus. Ms. Brownlee also received options exercisable
for 13,767 shares, exercisable at a weighted average price of $4.20 per share, and a restricted stock award of 1,712 shares, which
were issued at a price of $2.66 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(e)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 23, 2011, the Compensation Committee
of the Board of Directors of the Company approved the increase in base salary, the payment of cash bonuses and the issuance of
stock options to its executive officers: Michael Fonstein, Yakov Kogan, C. Neil Lyons, and Andrei Gudkov. The base salary increases,
which will go into effect on January 1, 2012, the payment of cash bonuses and the award of stock options are in recognition of
the Company&rsquo;s performance in 2011. The cash bonuses are payable in January 2012 and the stock options will be awarded in
compliance with the Company&rsquo;s Equity Award Guidelines and will vest immediately when granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table sets forth the new base salaries, cash bonuses
and stock options of these executive officers, as approved:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="font-weight: bold; text-decoration: underline">Name</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-decoration: underline">Base Salary</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-decoration: underline">Cash Bonus</TD>
    <TD STYLE="font-weight: bold; text-decoration: underline">Stock Options</TD></TR>
<TR STYLE="background-color: #CCFFCC">
    <TD STYLE="width: 24%">Michael Fonstein</TD>
    <TD STYLE="width: 1%">$</TD>
    <TD STYLE="width: 24%">341,356</TD>
    <TD STYLE="width: 1%">$</TD>
    <TD STYLE="width: 24%">30,179</TD>
    <TD STYLE="width: 26%">56,250</TD></TR>
<TR STYLE="background-color: white">
    <TD>Yakov Kogan</TD>
    <TD>&nbsp;</TD>
    <TD>266,685</TD>
    <TD>&nbsp;</TD>
    <TD>23,577</TD>
    <TD>56,250</TD></TR>
<TR STYLE="background-color: #CCFFCC">
    <TD>C. Neil Lyons</TD>
    <TD>&nbsp;</TD>
    <TD>254,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp; 7,500</TD>
    <TD>18,750</TD></TR>
<TR STYLE="background-color: white">
    <TD>Andrei Gudkov</TD>
    <TD>&nbsp;</TD>
    <TD>173,677</TD>
    <TD>&nbsp;</TD>
    <TD>24,476</TD>
    <TD>56,250</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 7.01 Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&rsquo;s press release announcing
the changes to management described in this Current Report on Form 8-K is furnished as Exhibit 99.1. The press release is not deemed
to be &quot;filed&quot; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;),
or otherwise subject to the liability of that section.&nbsp;&nbsp;This information will not be deemed to be incorporated by reference
into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the registrant specifically
incorporates it by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 9.01 Financial Statements and
Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-weight: bold"></TD>
    <TD STYLE="font-weight: bold"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(d)</TD>
    <TD COLSPAN="2" STYLE="font-size: 12pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; border-bottom: black 1.5pt solid; font-weight: bold">Exhibit No.</TD>
    <TD STYLE="width: 2%; font-size: 12pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 86%; border-bottom: black 1.5pt solid; font-weight: bold">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>99.1</TD>
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD>Press Release dated January 24, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold">CLEVELAND BIOLABS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR>
    <TD>Date: January 25, 2012</TD>
    <TD STYLE="vertical-align: top">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">&nbsp;/s/ Yakov Kogan</TD></TR>
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%; vertical-align: top">Name:</TD>
    <TD STYLE="width: 42%">&nbsp;Yakov Kogan, Ph.D., M.B.A.</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Title:</TD>
    <TD>Interim Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v300268_8k.htm", "secsgml_size_bytes": 16589}]
{"company-data": {"conformed-name": "CLEVELAND BIOLABS INC", "cik": "0001318641", "assigned-sic": "8731", "irs-number": "200077155", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-32954", "film-number": "12545910"}, "business-address": {"street1": "73 HIGH STREET", "city": "BUFFALO", "state": "NY", "zip": "14203", "phone": "(716) 849-6810"}, "mail-address": {"street1": "73 HIGH STREET", "city": "BUFFALO", "state": "NY", "zip": "14203"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported):
January 25, 2012 (January 23, 2012)
Cleveland BioLabs, Inc.
(Exact Name of Issuer as Specified in Charter)
DELAWARE
001-32954
20-0077155
(State or Other Jurisdiction of Incorporation or Organization)
(Commission File Number)
(I.R.S. Employer Identification Number)
73 High Street
14203
Buffalo, NY
(Zip Code)
(Address of Principal Executive Offices)
(716) 849-6810
(Registrant's Telephone Number, Including
Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) and (c)
On January 24, 2012, Cleveland BioLabs, Inc.
(the "Company") announced that Michael Fonstein, Ph.D. has stepped down from his position as Chief Executive Officer
of the Company. He will continue to serve as the President of the Company. The Company also announced that Yakov Kogan, Ph.D.,
M.B.A., the current Chief Operating Officer of the Company, will also be appointed to the position of interim Chief Executive Officer.
The above changes will take effect immediately.
The change is being implemented in order to
focus Dr. Fonstein's time and effort on advancing the CBLB502 program towards FDA licensure as a countermeasure for Acute
Radiation Syndrome, guiding promising business development opportunities and supporting recently established joint ventures. Dr.
Kogan, as interim Chief Executive Officer, will become the principal executive officer of the Company in charge of all of the Company's
strategic and operational activities. Both Dr. Fonstein and Dr. Kogan will remain employed as executives of the Company pursuant
to their existing employment agreements and will retain their positions as members of the Company's Board of Directors.
Prior to his appointment as interim Chief Executive
Officer, Dr. Kogan served as the Chief Operating Officer of the Company. His biographical information is contained in the Company's
proxy statement for the Company's 2011 Annual Meeting of Stockholders, and is incorporated herein by reference. Leah Brownlee,
who serves as the Company's General Counsel and Vice President of Corporate Compliance, is the spouse of Dr. Kogan. During
fiscal 2011, as compensation, Ms. Brownlee was paid $200,313 in cash salary and bonus. Ms. Brownlee also received options exercisable
for 13,767 shares, exercisable at a weighted average price of $4.20 per share, and a restricted stock award of 1,712 shares, which
were issued at a price of $2.66 per share.
(e)
On January 23, 2011, the Compensation Committee
of the Board of Directors of the Company approved the increase in base salary, the payment of cash bonuses and the issuance of
stock options to its executive officers: Michael Fonstein, Yakov Kogan, C. Neil Lyons, and Andrei Gudkov. The base salary increases,
which will go into effect on January 1, 2012, the payment of cash bonuses and the award of stock options are in recognition of
the Company's performance in 2011. The cash bonuses are payable in January 2012 and the stock options will be awarded in
compliance with the Company's Equity Award Guidelines and will vest immediately when granted.
The following table sets forth the new base salaries, cash bonuses
and stock options of these executive officers, as approved:
Name
Base Salary
Cash Bonus
Stock Options
Michael Fonstein
$
341,356
$
30,179
56,250
Yakov Kogan
266,685
23,577
56,250
C. Neil Lyons
254,500
7,500
18,750
Andrei Gudkov
173,677
24,476
56,250
Item 7.01 Regulation FD Disclosure.
The Company's press release announcing
the changes to management described in this Current Report on Form 8-K is furnished as Exhibit 99.1. The press release is not deemed
to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"),
or otherwise subject to the liability of that section.  This information will not be deemed to be incorporated by reference
into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the registrant specifically
incorporates it by reference.
Item 9.01 Financial Statements and
Exhibits
(d)
Exhibit No.
Description
99.1
Press Release dated January 24, 2012
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CLEVELAND BIOLABS, INC.
Date: January 25, 2012
By:
/s/ Yakov Kogan
Name:
Yakov Kogan, Ph.D., M.B.A.
Title:
Interim Chief Executive Officer